Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-23T00:40:50.250Z Has data issue: false hasContentIssue false
  • English
  • Français

AVP-923 as a Novel Treatment for Pseudobulbar Affect in ALS

Published online by Cambridge University Press:  15 February 2006

Laura E. Pope
Laura E. Pope
Affiliation:
Clinical and Regulatory Affairs, Avanir Pharmaceuticals, San Diego, CA 92121, USA; Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Pseudobulbar palsypathologic laughingpathologic cryingdextromethorphanquinidineamyotrophic lateral sclerosismultiple sclerosisclinical trialneurotherapeutics
Type
Review Article
Information
Progress in Neurotherapeutics and Neuropsychopharmacology , Volume 1 , Issue 1 , January 2006 , pp. 91 - 104
Copyright
© 2006 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andersen, G., Vestergaard, K., & Riis, J.O. (1993). Citalopram for post-stroke pathological crying. Lancet, 342, 837–839.Google Scholar
Annels, S.J., Ellis, Y., & Davies, J.A. (1991). Non-opioid antitussives inhibit endogenous glutamate release from rabbit hippocampal slices. Brain Research, 564, 341–343.Google Scholar
Arciniegas, D.B., & Topkoff, J. (2000). The neuropsychiatry of pathologic affect: an approach to evaluation and treatment. Seminars in Clinical Neuropsychiatry, 5, 290–306.Google Scholar
Baldessarini, R.J. (1985). Drugs and the treatment of psychiatric disorder. In: Gilman, A.G., Goodman, L.S., Rall, T.W., & Mujrad, F. (eds.), The Pharmacologic Basis of Therapeutics (7th ed.). New York: MacMillan, pp. 387–415.
Bittigau, P., & Ikonomidou, C. (1997). Glutamate in neurologic diseases. Journal of Child Neurology, 12, 471–485.Google Scholar
Black, D.W. (1982). Pathological laughter: a review of the literature. Journal of Nervous and Mental Disease, 170, 67–71.Google Scholar
Brooks, B.R., Thisted, R.A., Appel, S.H., Bradley, W.G., Olney, R.K., Berg, J.E., Pope, L.E., & Smith, R.A. (2004). Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine. A randomized trial. Neurology, 63, 1364–1370.Google Scholar
Burns, A., Russell, E., Stratton-Powell, H., Tyrell, P., O'Neill, P., & Baldwin, R. (1999). Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry, 14, 681–685.Google Scholar
Caroscio, J.T., Mulvihill, M.N., Sterling, R., & Abrams, B. (1987). Amyotrophic lateral sclerosis. Neurologic Clinics, 5, 1–8.Google Scholar
Dark, F.L., McGrath, J.J., & Ron, M.A. (1996). Pathological laughing and crying. Australian and New Zealand Journal of Psychiatry, 30, 472–479.Google Scholar
Debonnel, G., & de Montigny, C. (1996). Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sciences, 58, 721–734.Google Scholar
Droll, K., Bruce-Mensah, K., Otton, S.V., Gaedigk, A., Sellers, E.M., & Tyndale, R.F. (1998). Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics, 8, 325–333.Google Scholar
Ebert, B., Thorkildsen, C., Andersen, S., Christrup, L.L., & Hjeds, H. (1998). Opioid analgesics as noncompetitive N-methyl-d-aspartate (NMDA) antagonists. Biochemical Pharmacology, 56, 553–559.Google Scholar
Feinstein, A., Feinstein, K., Gray, T., & O'Connor, P. (1997). Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Archives of Neurology, 54, 1116–1121.Google Scholar
Gallagher, J.P. (1989). Pathologic laughter and crying in ALS: a search for their origin. Acta Neurologica Scandinavica, 80, 114–117.Google Scholar
Ganzini, L., Johnston, W.S., & Hoffman, W.F. (1999). Correlates of suffering in amyotrophic lateral sclerosis. Neurology, 52, 1434–1440.Google Scholar
Gillman, P.K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95, 434–441.Google Scholar
Grace, A.A., & Camm, A.J. (1998). Quinidine. New England Journal of Medicine, 338, 35–45.Google Scholar
Greenamyre, J.T. (1986) The role of glutamate in neurotransmission and in neurologic disease. Archives of Neurology, 43, 1058–1063.Google Scholar
Houpt, J.L., Gould, B.S., & Norris, F.H.J. (1977). Psychological characteristics of patients with amyotrophic lateral sclerosis (ALS). Psychosomatic Medicine, 39, 299–303.Google Scholar
House, A., Dennis, M., Molyneux, A., Warlow, C., & Hawton, K. (1989). Emotionalism after stroke. British Medical Journal, 298, 991–994.Google Scholar
Kamei, J., Mori, T., Igarashi, H., & Kasuya, Y. (1992). Serotonin release in nucleus of the solitary tract and its modulation by antitussive drugs. Research Communications in Chemical Pathology and Pharmacology, 76, 371–374.Google Scholar
Kaschka, W.P., Meyer, A., Schier, K.R., & Fröscher, W. (2001). Treatment of pathological crying with citalopram. Pharmacopsychiatry, 34, 254–258.Google Scholar
Klein, M., & Musacchio, J.M. (1989). High affinity dextromethorphan binding sites in guinea pig brain. Effect of sigma ligands and other agents. Journal of Pharmacology and Experimental Therapeutics, 251, 207–215.Google Scholar
Lieberman, A., & Benson, F. (1977). Control of emotional expression in pseudobulbar palsy. Archives of Neurology, 34, 717–719.Google Scholar
Mattson, M.P. (2003). Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Medicine, 3, 65–94.Google Scholar
Matute, C., Alberdi, E., Domercq, M., Perez-Cerda, F., Perez-Samartin, A., & Sanchez-Gomez, M.V. (2001). The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends in Neurosciences, 24, 224–230.Google Scholar
Maurice, T., & Lockhart, B.P. (1997). Neuroprotective and anti-amnesic potentials of sigma (σ) receptor ligands. Progress in Neuropsychopharmacology and Biological Psychiatry, 21, 69–102.Google Scholar
Maurice, T., Urani, A., Phan, V.L., & Romieu, P. (2001). The interaction between neuroactive steroids and the sigma1 receptor function: behavioral consequences and therapeutic opportunities. Brain Research Reviews, 37, 116–132.Google Scholar
Mega, M.S., Cummings, J.L., Salloway, S., & Malloy, P. (1997). The limbic system: an anatomic, phylogenetic, and clinical perspective. In: Salloway, S., Malloy, P., & Cummings, J.L. (eds.), The Neuropsychiatry of Limbic and Subcortical Disorders. Washington, DC: American Psychiatric Press, Inc., pp. 3–18.
Moore, S.R., Gresham, L.S., Bromberg, M.B., Kasarkis, E.J., & Smith, R.A. (1997). A self report measure of affective lability. Journal of Neurology Neurosurgery and Psychiatry, 63, 89–93.Google Scholar
Mukand, J., Kaplan, M., Senno, R.G., & Bishop, D.S. (1996). Pathological crying and laughing: treatment with sertraline. Archives of Physical Medicine and Rehabilitation, 77, 1309–1311.Google Scholar
Müller, U., Murai, T., Bauer-Wittmund, T., & von Cramon, D.Y. (1999). Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Injury, 13, 805–811.Google Scholar
Musacchio, J.M., Klein, M., & Canoll, P.D. (1989). Dextromethorphan and sigma ligands: common sites but diverse effects. Life Sciences, 45, 1721–1732.Google Scholar
Nahas, Z., Arlinghaus, K.A., Kotrla, K.J., Clearman, R.R., & George, M.S. (1998). Rapid response of emotional incontinence to selective serotonin reuptake inhibitors. Journal of Neuropsychiatry and Clinical Neurosciences, 10, 453–455.Google Scholar
O'Brien, P.C. (1984). Procedures for comparing samples with multiple endpoints. Biometrics, 40, 1079–1087.Google Scholar
Panitch, H., Thisted, R.A., Pope, L.E., & Berg, J.E. (2005). A double-blind, placebo-controlled, multicenter study to assess the safety and efficacy of AVP-923 (dextromethorphan/quinidine) in the treatment of pseudobulbar affect in patients with multiple sclerosis. American Academy of Neurology 57th Annual Meeting, Miami Beach, Florida, S46.001.
Parvizi, J., Anderson, S.W., Martin, C.O., Damasio, H., & Damasio, A.R. (2001). Pathological laughter and crying/a link to the cerebellum. Brain, 124, 1708–1719.Google Scholar
Pope, L.E., Khalil, M.H., Berg, J.E., Stiles, M., Yakatan, G.J., & Sellers, E.M. (2004). Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. Journal of Clinical Pharmacology, 44, 1132–1142.Google Scholar
Robinson, R.G., Parikh, R.M., Lipsey, J.R., Starkstein, S.E., & Price, T.R. (1993). Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry, 150, 286–293.Google Scholar
Richter, R.W. (2005). Pseudobulbar affect in dementia improved under treatment with dextromethorphan/quinidine (AVP-923). American Association for Geriatric Psychiatry Meeting, San Diego, California.
Schadel, M., Wu, D., Otton, S.V., Kalow, W., & Sellers, E.M. (1995). Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. Journal of Clinical Psychopharmacology, 15, 263–269.Google Scholar
Schiffer, R., & Pope, L.E. (2005). Review of pseudobulbar affect including a novel and new potential therapy. Journal of Neuropsychiatry and Clinical Neurosciences, 17, 447–454.Google Scholar
Schiffer, R.B., Herndon, R.M., & Rudick, R.A. (1985). Treatment of pathologic laughing and weeping with amitriptyline. New England Journal of Medicine, 312, 1480–1482.Google Scholar
Shaibani, A.T., Sabbagh, M.N., & Doody, R. (1994). Laughter and crying in neurologic disorders. Neuropsychiatry, 7, 243–250.Google Scholar
Smith, R., Berg, J., Pope, L., & Thisted, R. (2003). Distinguishing affective disorders in amyotrophic lateral sclerosis. 14th International Symposium on ALS/MND, Milan, Italy.
Smith, R.A., Moore, S.R., Gresham, L.S., Manley, P.E., & Licht, J.M. (1995). The treatment of affective lability in ALS patients with dextromethorphan. Neurology, 45, A330.Google Scholar
Starkstein, S.E., Migliorelli, R., Teson, A., Petracca, G., Chemerinsky, E., Manes, F., & Leiguarda, R. (1995) Prevalence and clinical correlates of pathological affective display in Alzheimer's disease. Journal of Neurology Neurosurgery and Psychiatry, 59, 55–60.Google Scholar
Tortella, F.C., Pellicano, M., & Bowery, N.G. (1989). Dextromethorphan and neuromodulation: old drug coughs up new activities. TiPS, 10, 501–507.Google Scholar
Wilson, S.A.K. (1924). Some problems in neurology. II: Pathological laughing and crying. Journal of Neurology and Psychopathology, IV, 299–333.Google Scholar
Zeilig, G., Drubach, D.A., Katz-Zeilig, M., & Karatinos, J. (1996). Pathological laughter and crying in patients with closed traumatic brain injury. Brain Injury, 10, 591–597.Google Scholar
Zhang, Y., Britto, M.R., Valderhaug, K.L., Wedlund, P.J., & Smith, R.A. (1992). Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clinical Pharmacology and Therapeutics, 51, 647–655.Google Scholar